EGCG has been shown to increase sensitivity of GBM and multiple other tumor cells to various cytotoxic agents including 5-fluorouracil, taxol, vinblastine, gemcitabine, and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in vitro, as well as doxorubicin, paclitaxel, or interferon-α2b in vivo, using a preclinical model of intracranially injected GBM cells (58). This evidence concerns the gene TNF and glioblastoma.